This application details the collaborative, leadership role of the Gynecologic Oncology Group (GOG) Statistical and Data Center (SDC) in determining the GOG research agenda and accomplishing its mission of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of Gynecologic malignancies. The SDC is comprised of four Divisions (Biostatistics and Science, Information Technology, Data Management, and Administration) and features unparalleled experience in clinical trials investigating gynecologic malignancies. Its members participate in every aspect of Group activities and are inherently involved in GOG Leadership. Specific responsibilities are governed by comprehensive SOPs and embrace all aspects of Group research, including concept development, study design, protocol conduct, data acquisition and quality control, analysis, and publication of results. This grant period has been highlighted by exciting, innovative advances. The SDC has entered into collaboration with the University at Buffalo, Roswell Park Cancer Institute, and the New York State Center of Excellence. This has provided an academic setting for the SDC, and greatly enhanced its scientific expertise with the infusion of faculty with diverse talents. Technologic advances have revolutionized GOG data management with the development and refinement of electronic data submission and specimen tracking. Management strategies have enhanced productivity and efficiency.

Public Health Relevance

The role of the SDC is highly relevant to research in gynecologic oncology. Its members have the responsibility to ensure that the design of the research is feasible, that the data are of high quality and analyzed appropriately, and ultimately, that the results are interpreted properly and disseminated in a timely fashion. The ability to professionally attain these objectives is essential to high quality research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Roswell Park Cancer Institute Corp
United States
Zip Code
Matulonis, Ursula A; Sill, Michael W; Makker, Vicky et al. (2018) A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol :
Boardman, Cecelia H; Brady, William E; Dizon, Don S et al. (2018) A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic On Gynecol Oncol 151:202-207
Felix, Ashley S; Cohn, David E; Brasky, Theodore M et al. (2018) Receipt of adjuvant endometrial cancer treatment according to race: anĀ NRG Oncology/Gynecologic Oncology Group 210 Study. Am J Obstet Gynecol 219:459.e1-459.e11
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Cosgrove, Casey M; Tritchler, David L; Cohn, David E et al. (2018) An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecol Oncol 148:174-180
Gee, Michael S; Atri, Mostafa; Bandos, Andriy I et al. (2018) Identification of Distant Metastatic Disease in Uterine Cervical and Endometrial Cancers with FDG PET/CT: Analysis from the ACRIN 6671/GOG 0233 Multicenter Trial. Radiology 287:176-184
Olawaiye, Alexander B; Java, James J; Krivak, Thomas C et al. (2018) Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 151:18-23
Hamilton, C A; Miller, A; Casablanca, Y et al. (2018) Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecol Oncol 148:275-280
Norquist, Barbara M; Brady, Mark F; Harrell, Maria I et al. (2018) Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res 24:777-783
Chan, John K; Brady, William; Monk, Bradley J et al. (2018) A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecol Oncol 150:247-252

Showing the most recent 10 out of 484 publications